Please try another search
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.
| Name | Age | Since | Title |
|---|---|---|---|
| Ei Yamada | 72 | 2001 | CEO, President & Representative Director |
| Norikazu Eiki | 77 | 2014 | External Independent Director |
| Makoto Hara | 74 | 2018 | External Independent Director |
| Ikuo Mori | - | 2025 | Standing Corporate Auditor |
| Hideyuki Yamanashi | - | 2025 | Corporate Auditor |
| Kiyotaka Hayashi | 69 | 2025 | Corporate Auditor |
| Yasue Mitsukura | 51 | 2025 | Independent Director |
| Naoya Sato | 65 | 2021 | Director of Corporate Development & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review